Regulatory News:
Dassault
Systèmes (Paris:DSY) (Euronext Paris: #13065, DSY.PA) today
announced its participation as lead investor in a €65 million Series B
financing for BioSerenity,
a startup developing a comprehensive and efficient health solution
involving textiles equipped with sensors and online telehealth services
to diagnose and monitor chronic pathologies. Three of the startup’s
existing investors, BPI, Idinvest and LBO, also participated in the
round. Dassault Systèmes will retain a seat on BioSerenity’s board of
directors.
The funds will be used to further develop BioSerenity’s solutions beyond
their initial focus on cardiovascular, neurology and sleep disorders, to
grow its business internationally, and to develop new solutions for
telemedicine.
Founded in 2014 and headquartered in Paris, BioSerenity – which has been
part of the 3DEXPERIENCE
Lab – is developing wearable medical devices and digital
point-of-care solutions that leverage textile innovation and artificial
intelligence, as well as electronic patient-reported outcome (ePRO),
internet of things and cloud technologies.
The startup provides hospitals and healthcare professionals with a
portfolio of fully-operated care services. BioSerenity also provides
pharmaceutical companies with turnkey solutions for companion
diagnostics. This full-stack approach helps hospitals run acts less
expensively and more efficiently, helps patients receive the right
diagnosis faster, and helps treatment development and delivery with the
collection of clinical and real-world data.
“Healthcare industry growth will be led by connected medical devices
offering possibilities to collect patient data in a cost-effective,
continuous way that ensures patient adherence and comfort, and helps the
medical community diagnose and treat conditions early on, paving the way
for outcome-based care. This is precisely the purpose of BioSerenity,”
said Claire Biot, Vice President, Life Sciences Industry, Dassault
Systèmes. “For many years, Dassault Systèmes has been investing in
building up the first end-to-end collaborative platform to accelerate
innovation in the Life Sciences industry for patient-centric experience.”
“With this new round of financing, we not only receive the means to
pursue our growth, we also reinforce our partnership with Dassault
Systèmes, a company that is at the forefront of innovation in
healthcare,” said Pierre-Yves Frouin, President, BioSerenity.
Social media:
Share this on Twitter: .@Dassault3DS invests in @BioSerenity to
reinforce its commitment to innovation in #telemedicine #3DEXPERIENCE
#digitalhealth #telehealth
Connect with Dassault Systèmes on Twitter
Facebook
LinkedIn
YouTube
Connect with BioSerenity on Twitter,
LinkedIn,
Website
For more information:
Dassault Systèmes’ industry solution experiences for the life sciences
industry: https://ifwe.3ds.com/life-sciences
Dassault Systèmes’ 3DEXPERIENCE platform, 3D design software, 3D Digital
Mock Up and Product Lifecycle Management (PLM) solutions: http://www.3ds.com
###
About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE Company, provides business and
people with virtual universes to imagine sustainable innovations. Its
world-leading solutions transform the way products are designed,
produced, and supported. Dassault Systèmes’ collaborative solutions
foster social innovation, expanding possibilities for the virtual world
to improve the real world. The group brings value to over 250,000
customers of all sizes, in all industries, in more than 140 countries.
For more information, visit www.3ds.com.
3DEXPERIENCE, the Compass logo and the 3DS logo, CATIA, SOLIDWORKS,
ENOVIA, DELMIA, SIMULIA, GEOVIA, EXALEAD, 3D VIA, BIOVIA, NETVIBES and
3DEXCITE are registered trademarks of Dassault Systèmes or its
subsidiaries in the US and/or other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190617005767/en/